The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression, and increased cardiovascular responsiveness to norepinephrine during oral glucose tolerance test

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3646-3652

  Jaakkola, Ulriikka ^a,b   Kuusela, Tom ^a   Jartti, Tuomas ^c   Pesonen, Ullamari ^a   Koulu, Markku ^a   Vahlberg, Tero ^a   Kallio, Jaana ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU CITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCOSE; INSULIN; LEUCINE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; PROLINE; CORBADRINE; PEPTIDE HORMONE; PREPRONEUROPEPTIDE Y; PROTEIN PRECURSOR;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD ANALYSIS; BODY MASS; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; FEMALE; FUNCTION TEST; GENETIC POLYMORPHISM; GENOTYPE; HEART RATE VARIABILITY; HUMAN; INSULIN RELEASE; MALE; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PRESSORECEPTOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; AMINO ACID SUBSTITUTION; BLOOD; BLOOD PRESSURE; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; METABOLISM; MISSENSE MUTATION; SECRETION;

ADULT; AMINO ACID SUBSTITUTION; BLOOD GLUCOSE; BLOOD PRESSURE; FEMALE; GENOTYPE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LEUCINE; MALE; MUTATION, MISSENSE; NEUROPEPTIDE Y; NORDEFRIN; PEPTIDE HORMONES; PROLINE; PROTEIN PRECURSORS;

EID: 21244492860     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0153     Document Type: Article

References (40)

1. Zukowska-Grojec Z 1995 Neuropeptide Y. A novel sympathetic stress hormone and more. Ann NY Acad Sci 771:219-233
2. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS 1998 Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83:187-195
3. Bischoff A, Michel MC 1998 Renal effects of neuropeptide Y. Pflugers Arch 435:443-453
4. Nilsson T, Lind H, Brunkvall J, Edvinsson L 2000 Vasodilation in human subcutaneous arteries induced by neuropeptide Y is mediated by neuropeptide Y Y1 receptors and is nitric oxide dependent. Can J Physiol Pharmacol 78:251-255
5. Bischoff A, Michel MC 1998 Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype. Endocrinology 139:3018-3021
6. Moltz JH, McDonald JK 1985 Neuropeptide Y: direct and indirect action on insulin secretion in the rat. Peptides 6:1155-1159
7. Wisialowski T, Parker R, Preston E, Sainsbury A, Kraegen E, Herzog H, Cooney G 2000 Adrenalectomy reduces neuropeptide Y-induced insulin release and NPY receptor expression in the rat ventromedial hypothalamus. J Clin Invest 105:1253-1259
8. Bennet WM, Wang ZL, Jones PM, Wang RM, James RF, London NJ, Ghatei MA, Bloom SR 1996 Presence of neuropeptide Y and its messenger ribonucleic acid in human islets: evidence for a possible paracrine role. J Clin Endocrinol Metab 81:2117-2120
9. Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U, Geng Y, Karvonen MK, Vainio-Jylha E, Pollonen M, Kaipio-Salmi K, Seppala H, Lee EW, Higgins RD, Zukowska Z 2004 Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med 36:232-240
10. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MI 1998 Association of a leucine(7)-to- proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 4:1434-1437
11. Ding B 2003 Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 110:1199-1204
12. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT 2001 Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 159:145-151
13. Karvonen MK, Koulu M, Pesonen U, Uusitupa MI, Tammi A, Viikari J, Simell O, Ronnemaa T 2000 Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children. J Clin Endocrinol Metab 85:1455- 1460
14. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J, Laakso M, Uusitupa MI 2000 Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 85:2266-2269
15. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, Laakso M, Uusitupa MI, Koulu M 2000 Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 108:235-236
16. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, Fagerudd JA, Groop PH, FinnDiane Study Group 2004 Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 27:503-509
17. Wallerstedt SM, Skrtic S, Eriksson AL, Ohlsson C, Hedner T 2004 Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 22:1277-1281
18. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen OJ, Uusitupa MI, Koulu M 2001 Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 15:1242-1244
19. Kallio J, Pesonen U, Karvonen MK, Kojima M, Hosoda H, Kangawa K, Koulu M 2001 Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. J Clin Endocrinol Metab 86:5348-5352
20. Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M 2003 Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J Clin Endocrinol Metab 88:3278-3283
21. 1996 Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 17:354-381
22. Hughson RL, Quintin L, Annat G, Yamamoto Y, Gharib C 1993 Spontaneous baroreflex by sequence and power spectral methods in humans. Clin Physiol 13:663-676
23. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K 2001 Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227-232
24. Anderwald C, Brabant G, Bernroider E, Horn R, Brehm A, Waldhausl W, Roden M 2003 Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 52:1792-1798
25. Scheinin M, Karhuvaara S, Ojala-Karlsson P, Kallio A, Koulu M 1991 Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of α2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci 49:75-84
26. McCulloch CE, Searle SR 2001 Generalized, linear, and mixed models. New York: John Wiley, Sons
27. Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U, Kallio J, Uusitupa M, Laakso M 2003 The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism 52:643-646
28. Cho YR, Kim CW 2004 Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun 314:773-780
29. Liao D, Cai J, Brancati FL, Folsom A, Barnes RW, Tyroler HA, Heiss G 1995 Association of vagal tone with serum insulin, glucose, and diabetes mellitus - the ARIC study. Diabetes Res Clin Pract 30:211-221
30. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K 2000 Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85:4908-4911
31. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194-198
32. Nakagawa E, Nagaya N, Okumura H, Enomoto M, Oya H, Ono F, Hosoda H, Kojima M, Kangawa K 2002 Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose. Clin Sci (Lond) 103:325-328
33. Misra M, Miller KK, Herzog DB, Ramaswamy K, Aggarwal A, Almazan C, Neubauer G, Breu J, Klibanski A 2004 Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. J Clin Endocrinol Metab 89:1605-1612
34. Gottero C, Bellone S, Rapa A, van Koetsveld P, Vivenza D, Prodam F, Benso A, Destefanis S, Gauna C, Bellone J, Hofland L, van der Lely AJ, Bona G, Ghigo E, Broglio F 2003 Standard light breakfast inhibits circulating ghrelin level to the same extent of oral glucose load in humans, despite different impact on glucose and insulin levels. J Endocrinol Invest 26:1203-1207
35. Briatore L, Andraghetti G, Cordera R 2003 Acute plasma glucose increase, but not early insulin response, regulates plasma ghrelin. Eur J Endocrinol 149:403-406
36. Holdstock C, Ludvigsson J, Karlsson FA 2004 Abnormal ghrelin secretion in new onset childhood type 1 diabetes. Diabetologia 47:150-151
37. Murdolo G, Lucidi P, Di Loreto C, Parlanti N, De Cicco A, Fatone C, Fanelli CG, Bolli GB, Santeusanio F, De Feo P 2003 Insulin is required for prandial ghrelin suppression in humans. Diabetes 52:2923-2927
38. Haberthur C, Schachinger H, Langewitz W, Ritz R 1999 Effect of β blockade with and without sympathomimetic activity (ISA) on sympathovagal balance and baroreflex sensitivity. Clin Physiol 19:143-152
39. Tovote P, Meyer M, Beck-Sickinger AG, von Horsten S, Ove Ogren S, Spiess J, Stiedl O 2004 Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regul Pept 120:205-214
40. Lombardi F 2002 Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev 6:245-249